On 2026-10-06, Barclays initiated coverage of ABT with a Overweight rating.
Barclays 于 2026-10-06 首次覆盖 ABT，初始评级为 增持（Overweight）。
For information only. Not investment advice.内容仅供参考，不构成投资建议。
ABT receives FDA approval for new CardioMEMS HF System capabilities that help patients engage in the care of their heart conditionAbbott Laboratories（ABT）的 new CardioMEMS HF System capabilities that help patients engage in the care of their heart condition 获美国 FDA 批准
Material Company Event · October 5, 2026公司公告 · 2026/10/5
ABT receives FDA approval for TactiFlex™ Duo Ablation CatheterAbbott Laboratories（ABT）的 TactiFlex™ Duo 消融导管 获美国 FDA 批准
Material Company Event · September 8, 2026公司公告 · 2026/9/8
Ford Robert B sells $46.2M of ABTFord Robert B 内部减持 雅培 (ABT) $46.2M
Insider Sale · August 27, 2026内部人减持 · 2026/8/27
